• Vancho Donev Bul Bio Author
  • Georgi Nikolov National Centre of Infecious and Parasitic Diseases Author



Intravenous Immunoglobulin (IVIg) were used for the first time at the late seventies for treatment of patient with primary and secondary immunodeficiencies. Тhe first observations opened a wide field for basic and clinical research leading to a rapidly expanding use of IVIg for the treatment of patients with multiple diseases. The immunoglobulin preparations contain large amount of intact form of IgG molecules with comparable values of subclasses as in native plasma. Тhose properties account for the normal half-life of injected immunoglobulin of three weeks, and its ability to react normal with the complement components and with the specific Fcγ-receptors on the surface of phagocytes and lymphocytes. IVIg is produced from plasma pules from several thousand donors, which leads to wide spectre of variable regions of IgG molecules in the product. Some of the antibodies in the product can recognize bacterial, virus and fungal antigens are essential in replacement therapy in patients with antibody deficiency. А good understanding of the molecular and cellular basis of the immunoregulatory actions of intravenous immunoglobulin preparations is important for optimizing their use in inflammatory diseases for conducting new clinical observations.


Download data is not yet available.


Ardekani, A. M., Liotta, L. A., Petricoin, E. F. 3rd, Expert Rev. Mol. Diagn. 2002, 2, 312 320.

Bruton O. C. Agammaglobulinemia Pediatrics 9 1952 722-728

L. Alecort, The evolution of comprehensive haemophilia care in the United States, perspectives from the frontline. Haemophilia, 22(2) (2016): 676-683.

H. Chapel, M. Lucas, M. Lee, et al. Common variable immunodeficiency disorders: Division into distinct clinical phenotypes. Blood, 112(2) (2008): 277-286.

Sheh-Li Chen. Economic Costs of Hemophilia and the Impact of Prophylactic Treatment on Patient Management. American Journal of Managed Care 22 no. 5 (2016): 126-133.

Putnam, R. W. The Plasma Proteins. Academic Press, New York 1975.

Beeck, H., Hellstern, P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma.Vox Sang. 1998, 74, 219-223.

Cohn, E.J., Strong, L.E., Hughes, W.L., Mulford, D.J., Ashworth, J.N., Melin, M., Taylor, H.L. Preparation and properties of serum and plasma proteins. IV. A system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J. Am. Chem. Soc. 1946, 68, 459-475.

Deutsch, H.F., Gösting, I.J., Alberty, R.A., Williams, J.W. Biophysical studies of blood plasma proteins. J. Biol. Chem. 1946, 164, 109-118.

J. L. Oncley, M. Melin, D. A. Richert, J. W. Cameron, and P. M. Gross. The Separation of the Antibodies, Isoagglutinins, Prothrombin, Plasminogen and β1-Lipoprotein into Subfractions of Human Plasma. J. Am. Chem. Soc. 1949, 71, 2, 541-550

Cohn, E.J., Gurd, F.R.N., Surgenor, D.M., Barnes, B.A., Brown, R.K., Derouaux, G., Gillespie, J.M., et al. A system for the separation of the components of human blood: Quantitative procedures for the separation of the protein components of human plasma. J. Am. Chem. Soc. 1950, 72, 465-474.

Kistler, P., Nitschmann, H.S. Large scale production of human plasma fractions. Vox Sang. 1962, 7, 414-424.

Dickler, H.B., Gelfand, E.W. Current perspectives on the use of intravenous immunoglobulin. Adv. Intern. Med. 1996, 41, 641-680.

Nikolova KA, Tchorbanov AI, Djoumerska-Alexieva IK, Nikolova M, Vassilev TL. Intravenous immunoglobulin up-regulates the expression of the inhibitory FcgammaIIB receptor on B cells. Immunol Cell Biol. 2009 Oct;87(7):529-33. Epub 2009 Jun 2. PMID: 19488062.

Ordman C. W., Jennings C. G. Jr., and Janeway C. A. Chemical, clinical and immunological studies on the products of human plasma fractionation. XII. The use of concentrated normal human serum gamma globulin in the prevention and attenuation of measles. J. Clin. Investig. 23 1944 541 -549

Connor E. and PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99 1997 93 -99

Lemieux, R., Bazin, R., Néron, S. Therapeutic intravenous immunoglobulins. Mol. Immunol. 2005, 42, 839-848.

Melehani JH, James DB, DuMont AL, Torres VJ, Duncan JA. 2015. Staphylococcus aureus leukocidin A/B (LukAB) kills human monocytes via host NLRP3 and ASC when extracellular, but not intracellular. PLoS Pathog 11: e1004970.

Kohler H, Bayry J, Nicoletti A et al. Natural autoantibodies as tools to predict the outcome of immune response. Scand J Immunol 2003, 58:285-289.

20. Li W, Fu M, An JG et al. Host defence against C. albicans infections in IgH transgenic mice with V(H) derived from a natural anti-keratin antibody. Cell Microbiol 2007, 9:306-315.

Dumont AL, Nygaard TK, Watkins RL, Smith A, Kozhaya L, Kreiswirth BN, Shopsin B, Unutmaz D, Voyich JM, Torres VJ. 2011. Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol Microbiol 79:814-825.

Yanagisawa C, Hanaki H, Natae T, Sunakawa K. 2007. Neutralization of staphylococcal exotoxins in vitro by human-origin intravenous immunoglobulin. J Infect Chemother 13:368 372.

Wood JB, Jones LS, Soper NR, Nagarsheth M, Creech CB, Thomsen IP. Commercial intravenous immunoglobulin preparations contain functional neutralizing antibodies against the Staphylococcus aureus leukocidin LukAB (LukGH). Antimicrob Agents Chemother 2017, 61: e00968-17.

Werden K. Supplemental immune globulins in sepsis. Clin. Chem. Lab. Med. 37 1999 341 -349

Douzinas E. E., Pitaridis M. T., Louris G., Andrianakis I., Katsouyanni K., Karmpaliotis D., Economidou J., Sfyras D., and Roussos C. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit. Care Med. 28 2000 8 -15 -1530

Sri Ramulu Elluru, Srini V Kaveri, Jagadeesh Bayry. The protective role of immunoglobulins in fungal infections and in ammation. Seminars in Immunopathology, Springer Verlag, 2014, in press.

Romani L. Immunity to fungal infections. Nat Rev Immunol 2011, 11:275- 288.

Wuthrich M, Deepe GS, Jr., Klein B. Adaptive immunity to fungi. Annu Rev Immunol 2012, 30:115-148.

van de Veerdonk FL, Kullberg BJ, van der Meer JW et al. Hostmicrobe interactions: innate pattern recognition of fungal pathogens. Curr Opin Microbiol 2008, 11:305-312.

Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998, 66:5771-5776.

Oncley, J.L., Melin, M., Richert, D.A., Cameron, J.W., Gross, P.M. The separation of the antibodies, isoagglutinins, prothrombin, plas minogen and ß1-lipoprotein into subfractions of human plasma. J. Am. Chem. Soc. 1998, 1949, 71, 541-550.

Vassilenko SM, Vassilev TL, Bozadjiev LG, Bineva IL, Kazarov GZ. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. Lancet. 1990 Mar 31;335(8692):791-2. PMID: 1969533.

Carlo Perricone, Paola Triggianese, Roberto Bursi, Giacomo Cafaro, Elena Bartoloni, Maria Sole Chimenti, Roberto Gerli and Roberto. Microorganisms Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections 2021, 9(1), 121;

Franchini M, Focosi D, Percivalle E, et al. Variant of concern-matched COVID-19 convalescent plasma usage in seronegative hospitalized patients. Viruses. 2022;14(7):1443.

Food and Drug Administration. Fact sheet for health care providers: Emergency Use Authorization (EUA) of COVID-19 convalescent plasma for treatment of coronavirus disease 2019 (COVID-19). 2021.

Shahzad M, Chaudhary SG, Zafar MU, et al. Impact of COVID-19 in hematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2022;24(2): e13792.

Lang-Meli J, Fuchs J, Mathé P, et al. Case series: convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency. J Clin Immunol. 2022;42(2):253-265.

Rodionov RN, Biener A, Spieth P, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microbe. 2021 ;2(4): e138.

Vancho Donev, Milena Alexova, Yana Dimitrova Todorova, Radoslava Emilova Grozdanova, Georgi Stoqnov Nikolov, Maria Hristiqnova Nikolova. Recovery plasma from patients with COVID-19 and intravenous immunoglobulin as rescue passive immunization in SARS-COV-2 infection. Bulgarian Journal of Clinical Immunology,2023, vol.16.

Bruton O. C. Agammaglobulinemia Pediatrics 9 1952 722-728







How to Cite

Donev, V.; Nikolov, G. THE POTENTIAL OF HUMAN PLASMA AND HUMAN BLOOD PRODUCTS FOR IMMUNE PROTECTION. Probl Infect Parasit Dis 2024, 52 (1), 22-28.

Most read articles by the same author(s)